Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Bumble Inc (BMBL) Price & Performance

BridgeBio Pharma IncTrade
Bumble IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Bumble Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Bumble Inc trades at $2.77 (market cap $359.61M). The key difference: BridgeBio Pharma Inc is far larger — about 46.2× Bumble Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Bumble Inc nearer its low. Which is the better fit depends on your goals.

BBIOBMBL
Market Cap
$16.61B$359.61M
Sector
HealthTechnology
52-Week High
$90.17$7.17
52-Week Low
$47.29$2.70
Enterprise Value
$18.16B$665.47M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

Bumble Inc

Bumble (BMBL) trades at $2.83, down 0.53% with bearish technical signals. The company reported mixed Q2 2026 results, beating earnings estimates but missing on revenue with declining paying users. Despite a gross margin of 72.84%, Bumble shows negative profitability metrics with -57.96% net margin and -87.65% ROE. Recent news indicates strategic shifts toward IRL events and AI matchmaking amid exploration of potential sale options.

Outlook remains challenging with significant execution risks. While valuation multiples appear attractive (P/S 0.39, P/B 0.72), persistent user declines and negative cash flow create headwinds. Analyst consensus leans Hold (73.91%) with $3.62 price target suggesting 28% upside, but success hinges on product transformation reversing user trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Bumble Inc

Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.

Read more on BMBL